An observational study in Sialorrhea, sponsored by Medstar Health Research Institute. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Medstar Health Research Institute · Observational
A retrospective, multicenter chart abstraction to investigate the prevalence of chronic sialorrhea, and the real-world use of incobotulinumtoxinA injections in male and female participants aged 18 years and older with chronic sialorrhea. Patients who come to a neurologic clinic in the past 6 months from the start date will be screened by searching for the ICD-10 code and diagnosis of sialorrhea and cross-referencing with those patients also being prescribed incobotulinumtoxinA. Data will be retrieved from the electronic medical record.
57 studies on the registry are indexed under Sialorrhea; 6 are open to participants now.
This study's enrollment of 206 is above the median of 90 across 11 observational studies indexed under Sialorrhea.
Browse Sialorrhea studies →Medstar Health Research Institute is the lead sponsor of 161 studies on the registry; 32 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 6 (43%) have results posted.
Counted across the registry records on this site, refreshed daily.
Recruitment occurs at MedStar Health-affiliated sites including:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Chart abstraction measured sialorrhea and its treatment in different neurological conditions
Chart abstraction measured sialorrhea and its treatment in different neurological conditions 11/1/2024 to 4/30/2025
Time frame: 6 months
Correlation between the onset of sialorrhea and disease state
Correlation between the onset of sialorrhea and disease state from 11/01/2014-04/01/2025
Time frame: 6 months
Dosage of incobotulinumtoxinA used per gland and overall, in the treatment of chronic sialorrhea.
Describe dosage of incobotulinumtoxinA used per gland and overall, in the treatment of chronic sialorrhea from 11/01/2024 to 04/01/2025
Time frame: 6 months
Dose development of incobotulinumtoxinA over time
Describe dose development of incobotulinumtoxinA over time for Siallorhea
Time frame: 6 months
Treatment pathway of sialorrhea
Describe treatment pathway of sialorrhea
Time frame: 6 months
Patient population receiving incobotulinumtoxinA for sialorrhea treatment
Describe patient population receiving incobotulinumtoxinA for sialorrhea treatment
Time frame: 6 months
Plan to share: No
Ran from Oct 2025 to primary completion in Mar 2026, 5 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medstar Health Research Institute →